51 patents
Utility
Methods of Treating Cancer Using Tigit-and Light-based Chimeric Proteins
18 Jan 24
The present disclosure relates, inter alia, to compositions and methods, including chimeric proteins that find use in the treatment of disease, and to detection and treatment of drug resistant cancer using chimeric proteins.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 3 Dec 21
Utility
Method of Determining Resistance to Checkpoint Inhibitor Therapies
11 Jan 24
The current disclosure relates to animal models, methods for screening and testing of an anti-cancer drug candidates, and to methods for treatment, evaluating efficacy of cancer treatment, and selecting patients for cancer therapy.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 3 Dec 21
Utility
Homodimeric and Heterodimeric Proteins Comprising Butyrophilin
28 Dec 23
The present disclosure relates, inter alia, to compositions and methods, including heterodimeric proteins and chimeric proteins comprising portions of butyrophilin family of proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 14 Apr 21
Utility
Methods of Identifying Gamma Delta T Cell-modulating Agents
21 Dec 23
The present invention relates to, in part, methods that are useful for cancer treatment, and methods for selecting personalized treatment regimens.
George FROMM, Suresh DE SILVA, Taylor SCHREIBER
Filed: 18 Nov 21
Utility
VSIG8-based chimeric proteins
5 Dec 23
The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
Taylor Schreiber, George Fromm, Suresh De Silva
Filed: 1 Nov 21
Utility
Heterodimeric proteins and uses thereof
10 Oct 23
The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
Taylor Schreiber, George Fromm, Suresh De Silva
Filed: 24 Mar 21
Utility
Heterodimeric Proteins and Uses Thereof
13 Jul 23
The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 17 Jan 23
Utility
Heterodimeric proteins for modulating gamma delta T cells
9 May 23
The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
Taylor Schreiber, George Fromm, Suresh De Silva
Filed: 1 Jun 22
Utility
TGFBR2-BASED Chimeric Proteins
16 Feb 23
The present invention relates, in part, to, chimeric proteins which include the extracellular domain of transforming growth factor beta receptor (TGFBR2) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
Taylor SCHREIBER, Casey SHUPTRINE, George FROMM, Suresh DE SILVA
Filed: 20 May 22
Utility
NK Cell-directed Chimeric Proteins
16 Feb 23
The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of a Type I transmembrane protein or a portion of a membrane-anchored extracellular protein and a portion of the extracellular domain of a Type II transmembrane protein, wherein the Type II transmembrane protein is naturally expressed on the surface of a Natural Killer (NK) cell that find use in the treatment of disease, such as cancer and viral infections.
Taylor SCHREIBER, Casey SHUPTRINE, George FROMM, Suresh DE SILVA
Filed: 14 Apr 22
Utility
Heterodimeric Proteins for Modulating Gamma Delta T Cells
19 Jan 23
The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 1 Jun 22
Utility
Methods of Making and Using Extracellular Domain-based Chimeric Proteins
6 Oct 22
The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.
Taylor SCHREIBER, George FROMM, Suresh DE SlLVA
Filed: 11 Apr 22
Utility
Chimeric Proteins In Autoimmunity
29 Sep 22
The present invention relates, inter alia, to compositions and methods, including chimeric proteins having a first domain comprising an extracellular domain of a first transmembrane protein, a first secreted protein, or a first membrane-anchored extracellular protein and a second domain comprising an extracellular domain of a second transmembrane protein, a second secreted protein, or a second membrane-anchored extracellular protein, in which either or both of the first domain and the second domain decreases self-directed immune system activity when bound to its ligand/receptor.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA, Louis GONZALEZ
Filed: 28 Aug 20
Utility
Chimeric Protein Expressing T-cells
18 Aug 22
The present invention relates to, inter alia, compositions and methods, including engineered T cells that express chimeric antigen receptors and heterologous chimeric proteins that find use in the treatment of cancer.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 22 Jun 20
Utility
Tigit- and Light-based Chimeric Proteins
21 Jul 22
The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 6 Apr 22
Utility
Combination Therapies
16 Jun 22
The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 27 Feb 20
Utility
Methods of making and using extracellular domain-based chimeric proteins
17 May 22
The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.
Taylor Schreiber, George Fromm, Suresh De Silva
Filed: 27 Feb 18
Utility
CSF1R-BASED Chimeric Proteins
12 May 22
The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 28 Jan 22
Utility
VSIG8-BASED Chimeric Proteins
21 Apr 22
The present invention relates, in part, to, chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
Taylor SCHREIBER, George FROMM, Suresh DE SILVA
Filed: 1 Nov 21
Utility
CSF1R-CD40L chimeric proteins
8 Mar 22
The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
Taylor Schreiber, George Fromm, Suresh De Silva
Filed: 27 Feb 18